INSERM UMR-S 939, Hôpital de la Pitié, F-75013, Paris, France.
J Biol Chem. 2011 May 13;286(19):17227-38. doi: 10.1074/jbc.M111.220483. Epub 2011 Mar 20.
Scavenger receptor SR-BI significantly contributes to HDL cholesterol metabolism and atherogenesis in mice. However, the role of SR-BI may not be as pronounced in humans due to cholesteryl ester transfer protein (CETP) activity. To address the impact of CETP expression on the adverse effects associated with SR-BI deficiency, we cross-bred our SR-BI conditional knock-out mouse model with CETP transgenic mice. CETP almost completely restored the abnormal HDL-C distribution in SR-BI-deficient mice. However, it did not normalize the elevated plasma free to total cholesterol ratio characteristic of hepatic SR-BI deficiency. Red blood cell and platelet count abnormalities observed in mice liver deficient for SR-BI were partially restored by CETP, but the elevated erythrocyte cholesterol to phospholipid ratio remained unchanged. Complete deletion of SR-BI was associated with diminished adrenal cholesterol stores, whereas hepatic SR-BI deficiency resulted in a significant increase in adrenal gland cholesterol content. In both mouse models, CETP had no impact on adrenal cholesterol metabolism. In diet-induced atherosclerosis studies, hepatic SR-BI deficiency accelerated aortic lipid lesion formation in both CETP-expressing (4-fold) and non-CETP-expressing (8-fold) mice when compared with controls. Impaired macrophage to feces reverse cholesterol transport in mice deficient for SR-BI in liver, which was not corrected by CETP, most likely contributed by such an increase in atherosclerosis susceptibility. Finally, comparison of the atherosclerosis burden in SR-BI liver-deficient and fully deficient mice demonstrated that SR-BI exerted an atheroprotective activity in extra-hepatic tissues whether CETP was present or not. These findings support the contention that the SR-BI pathway contributes in unique ways to cholesterol metabolism and atherosclerosis susceptibility even in the presence of CETP.
清道夫受体 B1(SR-BI)在很大程度上促进了小鼠的 HDL 胆固醇代谢和动脉粥样硬化形成。然而,由于胆固醇酯转运蛋白(CETP)的活性,SR-BI 在人类中的作用可能并不那么明显。为了研究 CETP 表达对与 SR-BI 缺乏相关的不利影响,我们将我们的 SR-BI 条件性敲除小鼠模型与 CETP 转基因小鼠进行了杂交。CETP 几乎完全恢复了 SR-BI 缺乏小鼠异常的 HDL-C 分布。然而,它并没有使肝 SR-BI 缺乏引起的血浆游离胆固醇与总胆固醇比值升高正常化。在肝脏缺乏 SR-BI 的小鼠中观察到的红细胞和血小板计数异常部分被 CETP 恢复,但红细胞胆固醇与磷脂比值升高仍未改变。SR-BI 的完全缺失与肾上腺胆固醇储存减少有关,而肝 SR-BI 缺乏导致肾上腺胆固醇含量显著增加。在这两种小鼠模型中,CETP 对肾上腺胆固醇代谢没有影响。在饮食诱导的动脉粥样硬化研究中,与对照组相比,肝 SR-BI 缺乏加速了 CETP 表达(4 倍)和非 CETP 表达(8 倍)小鼠的主动脉脂质病变形成。肝脏缺乏 SR-BI 的小鼠中,巨噬细胞向粪便的胆固醇逆向转运受损,CETP 无法纠正这种情况,这很可能是由于动脉粥样硬化易感性增加所致。最后,比较 SR-BI 肝缺乏和完全缺乏小鼠的动脉粥样硬化负担表明,即使存在 CETP,SR-BI 在肝外组织中也具有抗动脉粥样硬化作用。这些发现支持这样一种观点,即即使存在 CETP,SR-BI 途径也以独特的方式促进胆固醇代谢和动脉粥样硬化易感性。